Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.70 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.70 |
| ▸ | CSF1R | P07333 | 3/20 | 0.70 |
| ▸ | RET | P07949 | 3/20 | 0.70 |
| ▸ | MET | P08581 | 3/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.70 |
| ▸ | PIM1 | P11309 | 3/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.70 |
| ▸ | PRKACA | P17612 | 3/20 | 0.70 |
| ▸ | FLT3 | P36888 | 3/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.70 |
| ▸ | CDK8 | P49336 | 3/20 | 0.70 |
| ▸ | GSK3A | P49840 | 3/20 | 0.70 |
| ▸ | GSK3B | P49841 | 3/20 | 0.70 |
| ▸ | CDK7 | P50613 | 3/20 | 0.70 |
| ▸ | CDK9 | P50750 | 3/20 | 0.70 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.70 |
| ▸ | JAK3 | P52333 | 3/20 | 0.70 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.70 |
| ▸ | MST1R | Q04912 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31167562 | 0.88 | RET (0.58) | JAK2NTRK1CSF1RRETMET | |
| SCHEMBL8821159 | 0.88 | RET (0.58) | JAK2NTRK1CSF1RRETMET | |
| SCHEMBL8860392 | 0.84 | GSK3A (0.72) | JAK2NTRK1CSF1RRETMET | |
| SCHEMBL404434 | 0.82 | CHEK1 (1.00) | JAK2NTRK1CSF1RRETMET | |
| SCHEMBL8821144 | 0.82 | CHEK1 (0.70) | JAK2NTRK1CSF1RRETMET | |
| SCHEMBL8821183 | 0.79 | CHEK1 (0.65) | JAK2NTRK1CSF1RRETMET | |
| SCHEMBL8821146 | 0.79 | GSK3B (0.65) | JAK2NTRK1CSF1RRETMET | |
| SCHEMBL8821127 | 0.79 | GSK3A (0.65) | JAK2NTRK1CSF1RRETMET | |
| SCHEMBL8821175 | 0.79 | CHEK1 (0.65) | JAK2NTRK1CSF1RRETMET | |
| SCHEMBL8821160 | 0.79 | AURKA (0.65) | JAK2NTRK1CSF1RRETMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805184-B1 | IMIDAZO-BENZODIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-01-09 | — | — | EP | disclosed |
| US-8293730-B2 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20100075954-A1 | SUBSTITUTED IMIDAZO[1,5-A][1,2,4]TRIAZOLO[1,5-D][1,4]BENZODIAZEPINE DERIVATIVES | KNUST HENNER | 2010-03-25 | — | — | US | disclosed |
| US-7671048-B2 | Substituted imidazo [1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7514426-B2 | Substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7507728-B2 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1809297-B1 | IMIDAZO[1,5A]TRIAZOLO[1,5D]BENZODIAZEPINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| EP-1809297-A1 | IMIDAZO[1,5A]TRIAZOLO[1,5D]BENZODIAZEPINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| EP-1807432-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-18 | — | — | EP | disclosed |
| EP-1805184-A1 | IMIDAZO-BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006045429-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006045430-A1 | IMIDAZO-BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| US-20060084642-A1 | gamma-aminobutyric acid GABA receptors inverse agonists ; Alzheimer's disease, cognition enhancers; 10-methyl-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | US | disclosed |
| WO-2006040038-A1 | IMIDAZO [1, 5-A]TRIAZOLO[1, 5-D]BENZODIAZEPINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079507-A1 | Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-13 | — | — | US | disclosed |
| US-5631261-A | CENTRAL NERVOUS SYSTEM DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
| EP-0673377-B1 | NEW TRIAZOLOQUINAZOLINES, THEIR PRODUCTION AND THEIR USE | BASF AG (DE) | 1997-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084642-A1 | gamma-aminobutyric acid GABA receptors inverse agonists ; Alzheimer's disease, cognition enhancers; 10-methyl-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | GABRA3, GABRA1, GABRA4 | JAK2 3691/4885NTRK1 95/4885CSF1R 1076/4885 |
| US-20060079507-A1 | Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives | GABRA3, GABRA1, OXER1 | JAK2 3134/4885NTRK1 108/4885CSF1R 1618/4885 |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA1, GABRA4, GABRA5 | JAK2 719/4885NTRK1 610/4885CSF1R 1542/4885 |
| US-20100075954-A1 | SUBSTITUTED IMIDAZO[1,5-A][1,2,4]TRIAZOLO[1,5-D][1,4]BENZODIAZEPINE DERIVATIVES | GABRA1, GABRA5, ADRA1A | JAK2 1470/4885NTRK1 1173/4885CSF1R 1623/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | JAK2 1396/4885NTRK1 488/4885CSF1R 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.